Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment
18 Years
N/A
Both
Glioblastoma, Glioma
Trial Information
Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment
The following leucocyte subsets will be analyzed in whole blood before treatment and before
cycles 3, 5 and 7:
- Classical, intermediate, nonclassical and Tie2 expressing monocytes.
- Regulatory T cells (Treg).
- Myeloid Derived Suppressor cells (MDSCs) The variation of the absolute numbers (or
relative percentages) of the cells in the blood of patients will be correlated to the
response to treatment assessed according to the RANO criteria.
Inclusion Criteria:
- Patients with histologically proved recurrent glioblastoma or anaplasic glioma,
- Tumor recurrence documented by MRI at least 3 months after the end of radiotherapy or
chemotherapy.
- Patients for whom a treatment by bevacizumab is proposed by a multidisciplinary team
staff.
- Age ≥ 18.
- Signed informed consent.
- Affiliation to a social security coverage
Exclusion Criteria:
- Known Hepatitis B or C or HIV.
- Inclusion in another clinical trial.
- Patient having received an anti-angiogenic therapy.
- Pregnant or breast-feeding woman.
- Person deprived of liberty or under guardianship or trusteeship or judicial
protection
- Inability to give informed consent
- Person unable or unwilling to comply with the requirements of the protocol for
geographical, social or psychological reasons.
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Outcome Measure:
blood cells populations
Outcome Description:
Analysis of blood cells populations variation during treatment with bevacizumab. Last sampling planned before the 7th cycle of bevacizumab.
Outcome Time Frame:
up to 4 months
Safety Issue:
No
Principal Investigator
Veronique QUILLIEN, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Center Eugene Marquis
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
AVA-CELL
NCT ID:
NCT01836536
Start Date:
September 2012
Completion Date:
March 2015
Related Keywords:
- Glioblastoma
- Glioma
- High grade glioma
- Bevacizumab
- Chemotherapy
- Myeloid Cells
- Treg
- Glioblastoma
- Glioma
Name | Location |
|---|
